Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan schedules in refractory metastatic breast cancer
NCT00003351Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Aug 1998
- Primary completion
- Oct 2006
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of irinotecan in breast cancer (2 arms), sponsored by Cancer and Leukemia Group B. Primary endpoint: Time to progression up to 3 years. Started Aug 1998; status: completed.
02
Drugs
irinotecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00003351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003351.